CA2300154A1 - Sterile bioerodible implant device with improved biocompatability and method - Google Patents

Sterile bioerodible implant device with improved biocompatability and method Download PDF

Info

Publication number
CA2300154A1
CA2300154A1 CA002300154A CA2300154A CA2300154A1 CA 2300154 A1 CA2300154 A1 CA 2300154A1 CA 002300154 A CA002300154 A CA 002300154A CA 2300154 A CA2300154 A CA 2300154A CA 2300154 A1 CA2300154 A1 CA 2300154A1
Authority
CA
Canada
Prior art keywords
sterile
implant device
bioerodible implant
improved biocompatability
biocompatability
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002300154A
Other languages
French (fr)
Other versions
CA2300154C (en
Inventor
Orest Olejnik
Patrick M. Hughes
John S. Kent
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Sales, Inc.
Orest Olejnik
Patrick M. Hughes
John S. Kent
Allergan Sales, Llc
Allergan, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Sales, Inc., Orest Olejnik, Patrick M. Hughes, John S. Kent, Allergan Sales, Llc, Allergan, Inc. filed Critical Allergan Sales, Inc.
Publication of CA2300154A1 publication Critical patent/CA2300154A1/en
Application granted granted Critical
Publication of CA2300154C publication Critical patent/CA2300154C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/428—Vitamins, e.g. tocopherol, riboflavin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/45—Mixtures of two or more drugs, e.g. synergistic mixtures
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/602—Type of release, e.g. controlled, sustained, slow

Abstract

A plantable device is provided which incorpo-rates a retinoid for improving the biocompatibility of the device in tissue. The device may be bioerodible for the purpose of systemically or locally releasing a therapeutic agent in tissue or it may be a perma-nent implant which includes a surface treated with a retinoid for increasing the biocompatibility thereof.
CA002300154A 1997-08-11 1998-08-10 Sterile bioerodible implant device with improved biocompatability and method Expired - Fee Related CA2300154C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90809497A 1997-08-11 1997-08-11
US08/908,094 1997-08-11
PCT/US1998/016589 WO1999007418A2 (en) 1997-08-11 1998-08-10 Sterile bioerodible implant device with improved biocompatability and method

Publications (2)

Publication Number Publication Date
CA2300154A1 true CA2300154A1 (en) 1999-02-18
CA2300154C CA2300154C (en) 2008-07-08

Family

ID=25425169

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002300154A Expired - Fee Related CA2300154C (en) 1997-08-11 1998-08-10 Sterile bioerodible implant device with improved biocompatability and method

Country Status (9)

Country Link
US (3) US6074661A (en)
EP (1) EP1003569B1 (en)
JP (2) JP2001513369A (en)
AU (1) AU738338B2 (en)
CA (1) CA2300154C (en)
DE (1) DE69827138T2 (en)
ES (1) ES2232005T3 (en)
HK (1) HK1026377A1 (en)
WO (1) WO1999007418A2 (en)

Families Citing this family (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US20060280774A1 (en) * 1995-06-02 2006-12-14 Allergan, Inc. Compositions and methods for treating glaucoma
DE69827138T2 (en) * 1997-08-11 2006-02-23 Allergan, Inc., Irvine Sterile retinoid-containing biodegradable implant with improved biocompatibility and process for its preparation
US6306426B1 (en) * 1997-08-11 2001-10-23 Allergan Sales, Inc. Implant device with a retinoid for improved biocompatibility
CA2358296A1 (en) * 1999-01-05 2000-07-13 Anthony P. Adamis Targeted transscleral controlled release drug delivery to the retina and choroid
AU775149B2 (en) 1999-10-21 2004-07-22 Alcon Inc. Sub-tenon drug delivery
US7943162B2 (en) 1999-10-21 2011-05-17 Alcon, Inc. Drug delivery device
EP1473003B1 (en) 1999-10-21 2008-11-19 Alcon, Inc. Drug delivery device
US6416777B1 (en) * 1999-10-21 2002-07-09 Alcon Universal Ltd. Ophthalmic drug delivery device
US20040033241A1 (en) * 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
US6726918B1 (en) * 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
PT1313415E (en) * 2000-08-30 2008-11-25 Univ Johns Hopkins Devices for intraocular drug delivery
JP2004514702A (en) 2000-11-29 2004-05-20 オキュレックス　ファーマシューティカルズ，　インコーポレイテッド Intraocular implant for preventing transplant rejection in the eye
PT1409065E (en) 2001-07-23 2007-03-30 Alcon Inc Ophthalmic drug delivery device
DK1385452T3 (en) 2001-07-23 2007-01-15 Alcon Inc Device for administering an ophthalmic drug
FI118172B (en) 2002-04-22 2007-08-15 Inion Ltd Surgical implant
WO2003092665A2 (en) * 2002-05-02 2003-11-13 Massachusetts Eye And Ear Infirmary Ocular drug delivery systems and use thereof
ES2295647T3 (en) 2002-07-15 2008-04-16 Alcon, Inc. LIPOFIL PHARMACEUTICAL IMPLANT COMPOSITIONS, NOT POLYMER, FOR INTRAOCULAR USE
US20070184089A1 (en) * 2002-07-15 2007-08-09 Alcon, Inc. Non-Polymeric Lipophilic Pharmaceutical Implant Compositions for Intraocular Use
US20050048099A1 (en) 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
WO2004073551A2 (en) * 2003-02-18 2004-09-02 Massachusetts Eye And Ear Infirmary Transscleral drug delivery device and related methods
US8404269B2 (en) * 2003-04-11 2013-03-26 Michael Snyder Sustained release implantable eye device
EP1633320A2 (en) * 2003-05-02 2006-03-15 SurModics, Inc. Implantable controlled release bioactive agent delivery device
US8246974B2 (en) 2003-05-02 2012-08-21 Surmodics, Inc. Medical devices and methods for producing the same
US20040253293A1 (en) * 2003-06-16 2004-12-16 Afshin Shafiee Rate controlled release of a pharmaceutical agent in a biodegradable device
CN1805719A (en) * 2003-07-10 2006-07-19 爱尔康公司 Ophthalmic drug delivery device
US7585517B2 (en) * 2003-09-18 2009-09-08 Macusight, Inc. Transscleral delivery
US20050250737A1 (en) * 2003-11-12 2005-11-10 Allergan, Inc. Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
US20050101582A1 (en) * 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
US20060141049A1 (en) * 2003-11-12 2006-06-29 Allergan, Inc. Triamcinolone compositions for intravitreal administration to treat ocular conditions
US20070224278A1 (en) * 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
BRPI0417057A (en) * 2003-12-02 2007-03-13 Allergan Inc prevention and / or reduction of degeneration of a photoreceptor with retinoids
DE602005011928D1 (en) 2004-01-20 2009-02-05 Allergan Inc COMPOSITIONS FOR LOCALIZED THERAPY OF THE EYE, PREFERABLY CONTAINING TRIAMCINOLONE ACETONIDE AND HYALURONIC ACID
US8512738B2 (en) * 2004-04-30 2013-08-20 Allergan, Inc. Biodegradable intravitreal tyrosine kinase implants
US8147865B2 (en) * 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US20050244471A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Estradiol derivative and estratopone containing sustained release intraocular implants and related methods
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US8591885B2 (en) * 2004-04-30 2013-11-26 Allergan, Inc. Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems
US8673341B2 (en) * 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US20050244461A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Controlled release drug delivery systems and methods for treatment of an eye
US20070059336A1 (en) * 2004-04-30 2007-03-15 Allergan, Inc. Anti-angiogenic sustained release intraocular implants and related methods
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US8425929B2 (en) 2004-04-30 2013-04-23 Allergan, Inc. Sustained release intraocular implants and methods for preventing retinal dysfunction
AU2005240078A1 (en) * 2004-04-30 2005-11-17 Allergan, Inc. Retinoid-containing sustained release intraocular drug delivery systems and related methods of manufacturing
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US20050244462A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Devices and methods for treating a mammalian eye
US20050244458A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular neuropathies
US20050244463A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
US20070212395A1 (en) * 2006-03-08 2007-09-13 Allergan, Inc. Ocular therapy using sirtuin-activating agents
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US7771742B2 (en) 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
US20050244466A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Photodynamic therapy in conjunction with intraocular implants
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US20050244472A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Intraocular drug delivery systems containing excipients with reduced toxicity and related methods
US20050244478A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Anti-excititoxic sustained release intraocular implants and related methods
US8529927B2 (en) * 2004-04-30 2013-09-10 Allergan, Inc. Alpha-2 agonist polymeric drug delivery systems
US20050244500A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Intravitreal implants in conjuction with photodynamic therapy to improve vision
US20060182781A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Methods for treating ocular conditions with cyclic lipid contraining microparticles
US20060182783A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Sustained release intraocular drug delivery systems
US7589057B2 (en) 2004-04-30 2009-09-15 Allergan, Inc. Oil-in-water method for making alpha-2 agonist polymeric drug delivery systems
US20050244465A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Drug delivery systems and methods for treatment of an eye
US20060024350A1 (en) * 2004-06-24 2006-02-02 Varner Signe E Biodegradable ocular devices, methods and systems
BRPI0513243B8 (en) * 2004-07-12 2021-05-25 Allergan Inc ophthalmic compositions and their uses
WO2006023130A2 (en) * 2004-08-12 2006-03-02 Surmodics, Inc. Biodegradable controlled release bioactive agent delivery device
SI1848431T1 (en) * 2005-02-09 2016-05-31 Santen Pharmaceutical Co., Ltd. Liquid formulations for treatment of diseases or conditions
US8663639B2 (en) * 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
US20060233858A1 (en) * 2005-03-08 2006-10-19 Allergan, Inc. Systems and methods providing targeted intraocular drug delivery
EP1868661A1 (en) * 2005-04-08 2007-12-26 SurModics, Inc. Sustained release implants for subretinal delivery
US7931909B2 (en) * 2005-05-10 2011-04-26 Allergan, Inc. Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates
WO2006138675A2 (en) 2005-06-15 2006-12-28 The Ohio State University Research Foundation Her-2 peptides
KR20080033463A (en) 2005-07-27 2008-04-16 유니버시티 오브 플로리다 리서치 파운데이션, 아이엔씨. Small compounds that correct protein misfolding and uses thereof
CA2621657C (en) * 2005-09-21 2014-06-17 Surmodics, Inc. In situ occluding compositions comprising natural biodegradable polysaccharides polymerized by a redox pair
MX2007012061A (en) 2005-10-18 2007-12-13 Allergan Inc Ocular therapy using glucocorticoid derivatives selectively penetrating posterior segment tissues.
KR20080071188A (en) 2005-11-29 2008-08-01 스미스클라인 비참 코포레이션 Treatment method
US20070178138A1 (en) * 2006-02-01 2007-08-02 Allergan, Inc. Biodegradable non-opthalmic implants and related methods
US7964191B2 (en) 2006-02-02 2011-06-21 Allergan, Inc. Compositions and methods for the treatment of ophthalmic disease
JP5528708B2 (en) 2006-02-09 2014-06-25 参天製薬株式会社 Stable formulations and methods for preparing and using them
US8222271B2 (en) * 2006-03-23 2012-07-17 Santen Pharmaceutical Co., Ltd. Formulations and methods for vascular permeability-related diseases or conditions
US20070260203A1 (en) * 2006-05-04 2007-11-08 Allergan, Inc. Vasoactive agent intraocular implant
US7946296B2 (en) * 2006-05-26 2011-05-24 Philip Morris Usa Inc. Dissolvable tobacco film strips and method of making the same
US8668676B2 (en) * 2006-06-19 2014-03-11 Allergan, Inc. Apparatus and methods for implanting particulate ocular implants
US20070298073A1 (en) * 2006-06-23 2007-12-27 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US8802128B2 (en) 2006-06-23 2014-08-12 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US20080020014A1 (en) * 2006-07-19 2008-01-24 Paul Consigny Implantable devices containing nuclear receptor ligands for the treatment of vascular and related disorders
US20080097335A1 (en) * 2006-08-04 2008-04-24 Allergan, Inc. Ocular implant delivery assemblies
AR063275A1 (en) * 2006-10-12 2009-01-14 Epix Delaware Inc CARBOXAMIDE COMPOUNDS, A PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM AND ITS USE IN THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF DISEASES MEDIATED BY THE ACTIVATION OF CCR2.
US8039010B2 (en) 2006-11-03 2011-10-18 Allergan, Inc. Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
US8586556B2 (en) 2006-11-03 2013-11-19 Allergan, Inc. Methods, compositions and drug delivery systems for intraocular delivery of siRNA molecules
US8969415B2 (en) 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
EP2091482A2 (en) 2006-12-01 2009-08-26 Allergan, Inc. Method for determining optimum intraocular locations for drug delivery systems
US20080147021A1 (en) * 2006-12-15 2008-06-19 Jani Dharmendra M Drug delivery devices
US8846073B2 (en) 2006-12-19 2014-09-30 Allergan, Inc. Low temperature processes for making cyclic lipid implants for intraocular use
US20080265343A1 (en) * 2007-04-26 2008-10-30 International Business Machines Corporation Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof
US8231892B2 (en) 2007-05-24 2012-07-31 Allergan, Inc. Biodegradable drug delivery system
EP2207570A2 (en) 2007-09-14 2010-07-21 Nitto Denko Corporation Drug carriers
RU2010128543A (en) 2007-12-11 2012-01-20 Сайтопатфайндер, Инк. (Jp) CARBOXAMIDE COMPOUNDS AND THEIR APPLICATION AS AN CHEMOKIN RECEPTOR AGONISTS
US9877973B2 (en) 2008-05-12 2018-01-30 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US10588855B2 (en) 2008-05-12 2020-03-17 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US8202531B2 (en) * 2008-07-23 2012-06-19 Warsaw Orthopedic, Inc. Drug depots having one or more anchoring members
CN101386203B (en) * 2008-10-15 2011-09-14 广州卫视博生物科技有限公司 Manufacturing method of foldable artificial glass and die thereof
US9095506B2 (en) 2008-11-17 2015-08-04 Allergan, Inc. Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
US8034813B2 (en) * 2008-11-18 2011-10-11 Bausch & Lomb Incorporated Polymorphs of brimonidine pamoate
US8545554B2 (en) * 2009-01-16 2013-10-01 Allergan, Inc. Intraocular injector
US20100234283A1 (en) 2009-02-04 2010-09-16 The Ohio State University Research Foundation Immunogenic epitopes, peptidomimetics, and anti-peptide antibodies, and methods of their use
US8372036B2 (en) 2009-05-06 2013-02-12 Alcon Research, Ltd. Multi-layer heat assembly for a drug delivery device
IN2012DN00352A (en) 2009-06-16 2015-08-21 Bikam Pharmaceuticals Inc
WO2011039648A1 (en) 2009-09-30 2011-04-07 Glaxo Wellcome Manufacturing Pte Ltd. Methods of administration and treatment
WO2011057129A2 (en) 2009-11-09 2011-05-12 Allergan, Inc. Compositions and methods for stimulating hair growth
US8177747B2 (en) 2009-12-22 2012-05-15 Alcon Research, Ltd. Method and apparatus for drug delivery
EP2720539B1 (en) 2011-06-14 2018-10-24 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
US8772273B2 (en) 2011-10-04 2014-07-08 Quretino Therapeutics, Inc. Formulations and uses of retinoic acid receptor selective agonists
WO2013058809A1 (en) 2011-10-19 2013-04-25 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
JP6126118B2 (en) 2011-11-30 2017-05-10 ビカム ファーマスーティカルス，インコーポレイテッド Opsin binding ligands, compositions and methods of use
BR112014013106A2 (en) 2011-12-01 2017-06-13 Bikam Pharmaceuticals Inc opsin binding binders, compositions and methods of use
US9827401B2 (en) 2012-06-01 2017-11-28 Surmodics, Inc. Apparatus and methods for coating medical devices
MX351261B (en) 2012-06-01 2017-10-06 Surmodics Inc Apparatus and method for coating balloon catheters.
US11090468B2 (en) 2012-10-25 2021-08-17 Surmodics, Inc. Apparatus and methods for coating medical devices
WO2014127243A1 (en) 2013-02-15 2014-08-21 Allergan, Inc. Sustained drug delivery implant
WO2017173327A1 (en) 2016-03-31 2017-10-05 The Schepens Eye Research Institute, Inc. Endomucin inhibitor as an anti-angiogenic agent
US11229662B2 (en) 2016-11-15 2022-01-25 The Schepens Eye Research Institute, Inc. Compositions and methods for the treatment of aberrant angiogenesis
WO2019070917A1 (en) 2017-10-03 2019-04-11 The Schepens Eye Research Institute, Inc. Compounds and compositions for inhibiting retinal pigment epithelium degeneration and methods using the same
US11739326B2 (en) 2017-11-14 2023-08-29 Massachusetts Eye And Ear Infirmary RUNX1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition
US11628466B2 (en) 2018-11-29 2023-04-18 Surmodics, Inc. Apparatus and methods for coating medical devices
US11819590B2 (en) 2019-05-13 2023-11-21 Surmodics, Inc. Apparatus and methods for coating medical devices
CN111861124B (en) * 2020-06-18 2023-07-25 汕头大学 Identifiable performance evaluation method, identifiable performance evaluation system and storage medium applicable to injection molding machine
WO2023105417A1 (en) 2021-12-06 2023-06-15 Breye Therapeutics Aps Danegaptide formulation for applicatoin in the eye

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5456663A (en) * 1984-05-25 1995-10-10 Lemelson; Jerome H. Drugs and methods for treating diseases
GB8418772D0 (en) * 1984-07-24 1984-08-30 Geistlich Soehne Ag Chemical substances
DK498487A (en) * 1986-10-06 1988-04-07 Hoffmann La Roche UNKNOWN RETINOIDS
IT1196836B (en) * 1986-12-12 1988-11-25 Sorin Biomedica Spa Polymeric or metal alloy prosthesis with biocompatible carbon coating
US5602130A (en) * 1987-03-20 1997-02-11 Allergan Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity
US5234926A (en) * 1987-03-20 1993-08-10 Allergan, Inc. Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity
US4997652A (en) * 1987-12-22 1991-03-05 Visionex Biodegradable ocular implants
US4853224A (en) * 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
US5093360A (en) * 1989-04-07 1992-03-03 Yu Ruey J Retinal, derivatives and their therapeutic use
US5164188A (en) * 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
US5605930A (en) * 1991-10-21 1997-02-25 The United States Of America As Represented By The Department Of Health And Human Services Compositions and methods for treating and preventing pathologies including cancer
JPH08507715A (en) * 1993-03-18 1996-08-20 シーダーズ サイナイ メディカル センター Drug-inducing and releasable polymeric coatings for bioartificial components
US5716981A (en) * 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
WO1995003009A1 (en) * 1993-07-22 1995-02-02 Oculex Pharmaceuticals, Inc. Method of treatment of macular degeneration
US5679655A (en) * 1993-08-04 1997-10-21 Patent Biopharmaceutics, Inc. Method of treating lesions resulting from genital herpes with hyaluronic acid-urea pharmaceutical compositions
US5443505A (en) * 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US5466233A (en) * 1994-04-25 1995-11-14 Escalon Ophthalmics, Inc. Tack for intraocular drug delivery and method for inserting and removing same
US5534261A (en) * 1995-01-17 1996-07-09 University Of Southern California Retinoid-based compositions and method for preventing adhesion formation using the same
US5824685A (en) * 1995-02-01 1998-10-20 The Johns Hopkins University School Of Medicine Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
WO1997017091A1 (en) * 1995-11-08 1997-05-15 University Of South Florida Guinea pig model for leiomyomas and atherosclerosis
DE69827138T2 (en) * 1997-08-11 2006-02-23 Allergan, Inc., Irvine Sterile retinoid-containing biodegradable implant with improved biocompatibility and process for its preparation
US6306426B1 (en) * 1997-08-11 2001-10-23 Allergan Sales, Inc. Implant device with a retinoid for improved biocompatibility

Also Published As

Publication number Publication date
CA2300154C (en) 2008-07-08
US6074661A (en) 2000-06-13
AU738338B2 (en) 2001-09-13
EP1003569A2 (en) 2000-05-31
US6110485A (en) 2000-08-29
EP1003569B1 (en) 2004-10-20
WO1999007418A3 (en) 1999-06-03
WO1999007418A2 (en) 1999-02-18
JP2001513369A (en) 2001-09-04
DE69827138D1 (en) 2004-11-25
AU8777798A (en) 1999-03-01
JP2008272512A (en) 2008-11-13
HK1026377A1 (en) 2000-12-15
ES2232005T3 (en) 2005-05-16
US20080213338A1 (en) 2008-09-04
DE69827138T2 (en) 2006-02-23

Similar Documents

Publication Publication Date Title
CA2300154A1 (en) Sterile bioerodible implant device with improved biocompatability and method
EP0844008A4 (en) Device for use in the laser treatment of biological tissue (variants thereof)
AU3886199A (en) Medical device for dissolution of tissue within the human body
AU2777195A (en) Laser surgical procedure and device for cornea treatment
IL100069A0 (en) Laser radiation method and device for the treatment of body and dental tissues and bone
CA2392721A1 (en) Intervertebral disc treatment devices and methods
IL141088A0 (en) Sutureless implantable device and method for treatment of glaucoma
EP2027887A3 (en) Apparatus and method for treating body tissues with electricity or medicaments
AU2512901A (en) Implant for the closing of defect openings in the body of a human or animal and a system for the placement of such an implant
EP0953320A3 (en) Medical device
WO2004006990A3 (en) Medical device and method for tissue removal and repair
AU3594501A (en) A method and system for guiding a diagnostic or therapeutic instrument towards atarget region inside the patient's body
EP1065978A4 (en) Implantable therapeutic device and method
WO2001032121A3 (en) Skin-gripper
AU1577792A (en) Implantation tissue and treatment and use methods
AU7186501A (en) Methods for preventing neural tissue damage and for the treatment of alpha-synuclein diseases
GB9521253D0 (en) Biocompatible lubricious hydrophilic materials for medical devices
WO2002009735A3 (en) Methods and devices to modulate the wound response
DE60207265D1 (en) Heparin-stent
AU8372298A (en) Method and device for a combined heat treatment of body tissue
IL119757A0 (en) Finger-pressure functioning health-aid instrument for improving blood circulation in the human body
AU3218000A (en) Method and apparatus for placement of a bladder output control device
EP2202241A3 (en) Therapeutic compounds and methods for modulating V3, a versican isoform
DE29818536U1 (en) Device for supporting a patient's limbs during medical or therapeutic treatments
AU8732598A (en) Device and method for irradiating a patient's eye for photodynamic therapy

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20160810